Aytu Biopharma (AYTU) Common Equity (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Common Equity data on file, last reported at $35.1 million in Q1 2026.

• On a quarterly basis, Common Equity rose 0.7% year-over-year to $35.1 million in Q1 2026; TTM through Mar 2026 was $35.1 million, a 0.7% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, down 31.57% from the prior year.
• Common Equity for Q1 2026 stood at $35.1 million, up from $14.2 million in the prior quarter.
• Over the last five years, Common Equity for AYTU reached as high as $61.1 million in Q1 2022 and fell as low as $14.2 million in Q4 2025.
• Historically, Common Equity has averaged $34.7 million across 5 years, with a median of $32.9 million in 2023.
• On a YoY basis, Common Equity climbed as much as 95.07% in 2022 and fell as far as 67.79% in 2022.
• Year by year, Common Equity stood at $45.8 million in 2022, then slipped by 28.3% to $32.9 million in 2023, then slipped by 6.36% to $30.8 million in 2024, then plunged by 53.84% to $14.2 million in 2025, then jumped by 147.47% to $35.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $35.1 million in Q1 2026, $14.2 million in Q4 2025, and $23.2 million in Q3 2025.